Richard Alan Lafayette MD
Professor, Medicine - Nephrology, Stanford University Medical Center
Join to View Full Profile
300 Pasteur DrPalo Alto, CA 94305
Phone+1 650-725-6186
Fax+1 650-725-8418
Dr. Lafayette is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Nephrology, 1988 - 1991
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1985 - 1987
New York Medical CollegeClass of 1985
Certifications & Licensure
CA State Medical License 1988 - 2025
MA State Medical License 1992 - 1996
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM) Start of enrollment: 2005 Jun 01
- Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy Start of enrollment: 2009 Feb 01
- MEmbranous Nephropathy Trial Of Rituximab Start of enrollment: 2011 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy.Jürgen Floege, Richard Lafayette, Jonathan Barratt, Brian Schwartz, Paul T Manser
Kidney International. 2025-06-26 - Clinical Outcomes in the Nephrotic Syndrome Study Network: Disease Burden and Treatment Patterns over Time.Yelena Drexler, Ambarish Athavale, Abigail R Smith, Qian Liu, Jarcy Zee
Glomerular Diseases. 2025-06-05 - Expert Discussion on Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Challenges and Considerations.Richard A Lafayette, Vivek Charu, Richard J Glassock
Advances in Therapy. 2025-05-01
Journal Articles
- Cause of Kidney Disease and Cardiovascular Events in a National Cohort of US Patients with End-Stage Renal Disease on Dialysis: A Retrospective AnalysisWolfgang C Winkelmayer, Richard A Lafayette, European Heart Journal
Abstracts/Posters
- Facing the Vexing Problem of Recurrent FSGS After Kidney TransplantationRichard Lafayette, MD, American Society of Nephrology, Orlando, FL, 12/7/2019
- Facing the Vexing Problem of Recurrent FSGS After Kidney TransplantationRichard Lafayette, MD, American Society of Nephrology, Orlando, FL, 12/7/2019
Press Mentions
Atacicept Significantly Reduces Proteinuria in IgA Nephropathy: Phase 3 Trial ResultsJune 19th, 2025- 2024 Updates in IgA NephropathyApril 8th, 2025
- FDA Grants Accelerated Approval to Atrasentan for IgA NephropathyApril 4th, 2025
- Join now to see all
Grant Support
- Oral Calcimimetic Agent In Secondary HyperparathyroidismNational Center For Research Resources2000–2001
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
